Wound Care Audit Defense · CMS · DOJ · HHS-OIG · Skin Substitute FCA · Debridement

Skin Substitute FCA Defense Attorneys

FCA enforcement in wound care: Apex paid $309M, Vohra $45M.

DOJ secured a $309 million False Claims Act settlement with Apex Medical in January 2026 covering more than $1 billion in alleged false claims for unnecessary skin substitutes. Vohra Physicians Management settled $45 million for unnecessary debridement in November 2025.

CMS reclassified skin substitutes effective January 1, 2026 with a flat $127 per square centimeter reimbursement, only 18 covered products, and multi-year prepayment review. The WISeR Model launches AI-driven prior authorization in six states. Health Law Alliance defends wound care providers, skin substitute prescribers, and debridement physicians facing CMS prepayment review, UPIC audits, and FCA exposure.

$309M+

Apex Medical FCA Settlement (Jan 2026 Industry Comparable)

$127/sq cm

CMS Reclassified Skin Substitute Reimbursement

5,000+

Healthcare Defense Matters Handled

24/7

Emergency Response, Notice to Resolution

Wound Care Defense Hotline · Direct Line

(800) 345 - 4125

Speak with counsel who defends wound care matters at CMS, UPIC, and DOJ. Privileged. Available 24/7.

CMS prepayment review can stop cash flow within 60 days. Call now.

Request a privileged wound care defense review

Free, confidential. A Health Law Alliance attorney reviews the matter and calls you within 2 hours.

First Name

Last Name

Practice or Company Name

Phone

What Has Triggered the Audit or Investigation?

Brief Summary (optional)

100% Confidential · No obligation · Attorney-client privilege applies

What Happens Next

Within 2 hours: A Health Law Alliance attorney reviews your matter and the procedural posture.

Same day: Strategy call. We walk you through the contractor's methodology, the deadlines, and the defense plan for your specific claim type.

Engaged or not: You leave the call with a clear read on the matter. No pressure, no retainer required.

The Stakes

A wound care matter is rarely a single proceeding

CMS contractor audit. UPIC review. DOJ civil FCA exposure. Potential criminal referral. The same conduct often produces parallel proceedings across four agencies, each with its own evidentiary standard and resolution mechanism.

FCA exposure with treble damages
CMS prepayment review can stop cash flow
Personal liability and program exclusion

FCA exposure with treble damages

Skin substitute and debridement billing under the False Claims Act carries per-claim penalties of up to $28,619 per claim, with treble damages on top. The Apex Medical $309M settlement and the Vohra $45M settlement establish industry comparables. Settlements typically reach 1.5x to 3x the alleged false billings.

Financial Exposure

CMS prepayment review can stop cash flow

Once a wound care practice is placed on prepayment review, every claim is reviewed before payment. Cash flow stops for 60 to 180 days while reviews complete. Multi-year prepayment review under the new CMS framework can extend that posture for years. Most practices cannot operate through extended prepayment review without external financing.

Operational Exposure

Personal liability and program exclusion

Officers, owners, and prescribing physicians face individual exposure under the False Claims Act. A criminal conviction triggers automatic Medicare and Medicaid exclusion for 5+ years. Even a civil settlement can trigger administrative exclusion in some matters. Exclusion typically ends a wound care practice.

Personal & Administrative Exposure

Why Wound Care Defense Is Different in 2026

Four structural changes make 2026 wound care matters fundamentally different from prior years

The DOJ's 2025-2026 enforcement wave, the CMS reclassification, and the WISeR Model together change how wound care matters get audited, charged, and resolved. The defense playbook for 2024 does not apply.

Factor 01

DOJ has named wound care as an enforcement priority.

The Apex Medical $309M settlement (January 2026) and the Vohra $45M settlement (November 2025) are not isolated. DOJ's FY2026 enforcement priorities memorandum explicitly identifies wound care, skin substitute billing, and unnecessary debridement as focus areas. The pattern of investigation has been published. Practices that match the pattern are on the radar whether or not they have received a notice.

Factor 02

CMS reclassification rewrites the reimbursement math.

Effective January 1, 2026: only 18 covered skin substitute products, flat $127 per square centimeter reimbursement, multi-year prepayment review. The new framework also affects how prior billings are evaluated on retrospective review. A claim that complied with the old rules may be re-reviewed under the new methodology in some matters. The reimbursement math and the audit math have both changed.

Factor 03

WISeR Model adds AI-driven prior authorization.

The CMS WISeR Model launches AI-driven prior authorization in six pilot states in 2026. AI denials carry their own appeal mechanics distinct from human prior auth denials. The "explainability" of the AI denial becomes a defense issue. Practices in the pilot states face an additional procedural layer that did not exist in 2025.

Factor 04

Four-track investigation cascade is the norm.

A single wound care matter typically involves CMS contractor audit (UPIC, RAC, MAC, or ZPIC) plus DOJ civil FCA review plus HHS-OIG plus state Medicaid Fraud Control Unit. Each has its own evidentiary standard, timeline, and resolution mechanism. Defense response that addresses one track without coordinating the others creates unfixable leaks across the four proceedings.

The HLA Wound Care Defense Process

A four-stage protocol that addresses the four-track investigation cascade

Our bench includes a former federal prosecutor who handled healthcare fraud at DOJ, plus senior healthcare-company counsel. We coordinate defense across CMS contractor proceedings, DOJ FCA matters, HHS-OIG action, and state Medicaid Fraud Control Unit referrals. The four tracks are addressed as one matter.

Notice triage and contractor identification
Clinical defense build, claim by claim
Contractor and CMS engagement
FCA defense and federal court

Notice triage and contractor identification

Within 24 hours: identify the contractor (UPIC, RAC, MAC, ZPIC, or CMS prepayment review), confirm the audit scope and date range, calendar every deadline, place a litigation hold on clinical records and prior auth chains, and confirm whether parallel proceedings (DOJ, OIG, state MFCU) are open.

Clinical defense build, claim by claim

For each flagged claim: reconstruct medical necessity against the LCD or NCD in force at the date of service, verify skin substitute coverage criteria, document wound progression, defend debridement coding (CPT 11042 to 11047) under the documented wound condition. Every flagged claim gets its own defense memo before any contractor response is filed.

Contractor and CMS engagement

Direct engagement with the CMS contractor and, where applicable, the regional CMS office. Prepayment review terms can be negotiated when the substantive defense is strong. ALJ hearings, Medicare Appeals Council review, and Provider Reimbursement Review Board proceedings get drafted and filed within their statutory windows.

FCA defense and federal court

When the matter escalates to FCA exposure: pleading-stage motions, Rule 9(b) particularity challenges, government engagement, settlement or trial preparation. We have secured FCA dismissals in healthcare fraud matters by attacking the specificity of the relator's allegations. The same playbook applies to wound care FCA defense.

Common Wound Care Audit Triggers

The six patterns that put a wound care practice on the CMS or DOJ radar

If any of these describe your 2024 to 2026 wound care billing, the audit pool is already populated. Most contractors build the case before they send the notice.

Skin substitute volume above peer benchmark.

CMS contractor analytics flag practices with high per-patient skin substitute application rates compared to specialty peers. Repeat applications on the same wound, applications above the documented wound size, and applications without documented healing trajectory all draw review.

Repeated CPT 11042 to 11047 debridement coding.

High-frequency debridement billing for the same patient or wound triggers post-Vohra contractor review. Documentation of necrotic tissue removal, depth, and wound condition at each visit is the defense, and contractors look for gaps.

Wound progression documentation gaps.

Missing wound measurements, missing wound photographs, missing healing trajectory notes. Each gap allows the contractor to challenge medical necessity and to question whether ongoing treatment was supported by the clinical record.

Off-list or non-covered product use.

Use of skin substitute products not on the CMS covered list (effective January 1, 2026: only 18 covered products) creates near-automatic claim denials and prepayment review escalation. Claims billed under prior coverage rules face retrospective review under the new methodology.

Practice-wide utilization above peer benchmarks.

A practice in the top decile of any peer comparison metric (skin substitute units per patient, debridement frequency, hyperbaric utilization) is materially more likely to draw a UPIC or DOJ review than a practice at the median, regardless of actual compliance posture.

Patient family complaint or qui tam filing.

A complaint to the HHS-OIG hotline from a patient family member, a former employee, or a competitor often initiates a federal investigation. Qui tam complaints filed under seal can run for one to three years before the practice is notified.

Defense Outcomes That Apply to Wound Care Matters

Representative Case Results

Wound care FCA matters use the same Rule 9(b) particularity defense, the same pre-charge advocacy pattern, and the same federal indictment defense framework as the matters below. Outcomes are summarized for confidentiality. Wound-care-specific outcomes will be added as the firm's 2026 matters resolve.

FCA Dismissed

False Claims Act Lawsuit Against Healthcare Practice Dismissed.

Healthcare practice faced a False Claims Act lawsuit alleging multi-million dollar billing fraud. Health Law Alliance attorney Anthony Mahajan secured dismissal at the pleading stage on grounds that the relator failed to plead the alleged fraud with the particularity required under Rule 9(b). The same defense framework applies to wound care FCA matters.

Mid-Atlantic · Specialty practice · 2024

DOJ Declination

DOJ Declines Criminal Prosecution of Alleged $6M Fraud.

Healthcare company faced alleged $6M healthcare fraud allegations across multiple federal districts. After Health Law Alliance's pre-charge presentation to prosecutors and factual rebuttal of the government's theory, DOJ declined criminal prosecution. Pre-charge advocacy is the highest-leverage move in wound care matters as well.

National scope · Healthcare company · 2024

Indictment Dismissed

Federal Healthcare Fraud Indictment Dismissed Pre-Trial.

Solo physician faced a multi-count federal indictment for alleged healthcare fraud. Health Law Alliance filed responsive motions, built the procedural record, and challenged the government's theory; the indictment collapsed before trial. The same procedural posture applies to wound care criminal exposure.

Northeast · Solo physician · 2025

Attorney advertising. Prior results do not guarantee a similar outcome. Case summaries are generalized for confidentiality and are not a substitute for legal advice on your specific matter.

Client Reviews

What Clients Say

Survam Patel

Google review · a year ago

Anthony's background as a former federal prosecutor and executive for major healthcare companies provided a level of expertise and insight that made all the difference. His deep understanding of healthcare law, particularly in litigation and compliance matters, helped navigate complex legal issues with ease.
Andy Ayoub

Google review · a year ago

Anthony and his staff have gone above and beyond. His proactive communication and ability to handle complex legal scenarios effectively have been a significant asset. Highly recommended attorney.
Seth M.

Google review · Independent Pharmacist, Michigan

Top-notch attorneys with an unparalleled scope of experience and breadth of knowledge. You will want them in your corner.
Faris Gammoh

Google review · 9 months ago

Had nothing but great experience from them. Knowledgeable and professional in all aspects. They have a vast knowledge in health care cases, great to be on your side against insurances.
Ali M.

Google review · Local Guide

Trustworthy and experienced.

Wound Care Audit Defense FAQ

Frequently Asked Questions

Seven questions that come up on almost every first call. The answers below are general; specific situations require privileged consultation.

What is the WISeR Model and how does it affect wound care audits? +

The WISeR Model (Wasteful and Inappropriate Service Reduction Model) is a CMS demonstration that introduces AI-driven prior authorization for selected services in six pilot states starting in 2026. For wound care providers in pilot states, certain skin substitute applications and other services require pre-service authorization processed through an AI-assisted review system. AI denials carry their own appeal mechanics and the explainability of the AI denial often becomes a defense issue. Practices in pilot states face an additional procedural layer that did not exist in 2025. The defense for an AI denial often turns on whether the model relied on accurate clinical inputs and whether the denial reasoning maps to a coverage criterion that is actually applicable to the claim.

How does CMS prepayment review actually work? +

Prepayment review means every claim from the practice is reviewed by the contractor before payment. The practice submits claims as usual but cash flow stops until each claim clears review. Reviews can take 60 to 180 days per claim. Multi-year prepayment review under the new CMS framework can extend that posture for 18 to 36 months. Most practices cannot operate through extended prepayment review without external financing or a substantial cash reserve. Defense strategy focuses on getting off prepayment review as quickly as the substantive defense allows, often through a reduction-in-error-rate showing or a corrective action plan that the contractor accepts as resolution.

What documentation does my wound care practice need for skin substitute claims under the new CMS rules? +

Effective January 1, 2026, CMS coverage requires: confirmation that the product is on the 18-product covered list; documentation of wound type, location, depth, and measurements at each application; evidence of failed conservative treatment (typically four weeks of standard care); ongoing wound assessment with measurements and photographs at each visit; documentation of healing trajectory or rationale for continued application. The flat $127 per square centimeter reimbursement applies regardless of product cost, which changes the economic posture of high-cost products. Practices that used products outside the covered list before January 1, 2026 may face retrospective review under the new methodology in some matters.

Can I be personally liable in a wound care FCA case? +

Yes. Officers, owners, and prescribing physicians face personal liability under the False Claims Act when the government can establish that the individual knew of, or acted with reckless disregard toward, the false claim. The Apex Medical and Vohra cases both involved personal liability theories against individuals in addition to corporate exposure. Personal liability is not automatic, but it is a real exposure in any wound care FCA matter. Defense strategy addresses the personal-liability theory from day one to avoid locking in a posture that hurts the individual defendant later.

What is the Apex Medical case and why does it matter for my practice? +

In January 2026, DOJ secured a $309 million False Claims Act settlement with Apex Medical covering more than $1 billion in alleged false claims for unnecessary amniotic skin substitutes. The case set the industry comparable for skin substitute FCA matters and signaled DOJ's intention to pursue similar matters across the wound care space. Practices that share patterns with Apex Medical (high per-patient skin substitute volume, repeat applications without documented healing progression, off-list product use) are now in a higher-risk posture than they were in 2024. The Apex case is the reference point in every conversation between wound care defense counsel and a DOJ prosecutor.

Is debridement coding under CPT 11042-11047 a higher audit risk in 2026? +

Yes, in the wake of the November 2025 Vohra Physicians Management $45 million settlement for alleged unnecessary surgical debridement. Vohra established a contractor and DOJ playbook for debridement billing review that focuses on: frequency of debridement on the same wound, depth-of-debridement coding accuracy (CPT 11042 partial-thickness vs. 11043 full-thickness vs. 11044 deeper), documented necrotic tissue at each visit, and wound progression that justifies repeated debridement. Practices with high CPT 11042 to 11047 utilization should anticipate contractor review and should ensure the clinical documentation supports the depth code billed at each visit.

How long does a CMS prepayment review typically last? +

It depends on the contractor, the error rate the contractor finds in the reviewed claims, and whether the practice produces a corrective action plan that the contractor accepts. Standard prepayment review can run 6 to 12 months. Multi-year prepayment review under the post-2026 CMS framework can run 18 to 36 months. The fastest path off prepayment review is to demonstrate a sustained low error rate across the reviewed claims, which requires both the substantive clinical defense and the procedural engagement with the contractor's review process. Practices that respond passively to prepayment review remain on it longer than practices that engage actively.

Speak with Wound Care Defense Counsel Today

What changed in wound care enforcement for 2026

Before the contractor escalates the audit, before the FCA matter unseals, before CMS prepayment review stops your cash flow, have a privileged conversation with attorneys who defend wound care matters across CMS, UPIC, DOJ, and HHS-OIG. Free, confidential, no retainer.

"We received a UPIC audit notice citing both skin substitute and debridement claims. By week two, Health Law Alliance had reconstructed every flagged claim against the LCD in force on the date of service and identified three contractor methodology errors. The audit closed without recoupment six months later. The clinical defense was always going to be solid; what we needed was the legal framework around it." - Practice administrator, wound care practice (anonymized client, 2025)

CMS prepayment review does not wait. We answer 24/7.